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ARTICLE
A recurrent kinase domain mutation in PRKCA
defines chordoid glioma of the third ventricle
Benjamin Goode1, Gourish Mondal1, Michael Hyun1, Diego Garrido Ruiz 2, Yu-Hsiu Lin3, Jessica Van Ziffle1,4,
Nancy M. Joseph1,4, Courtney Onodera4, Eric Talevich4, James P. Grenert1,4, Iman H. Hewedi5, Matija Snuderl6,
Daniel J. Brat7, Bette K. Kleinschmidt-DeMasters8, Fausto J. Rodriguez 9, David N. Louis10, William H. Yong11,
M. Beatriz Lopes12, Marc K. Rosenblum13, Nicholas Butowski14, Tarik Tihan1, Andrew W. Bollen1,
Joanna J. Phillips1,14, Arun P. Wiita 2,3, Iwei Yeh1,4, Matthew P. Jacobson2, Boris C. Bastian1,4,
Arie Perry 1,14 & David A. Solomon 1,4
Chordoid glioma is a rare brain tumor thought to arise from specialized glial cells of the
lamina terminalis along the anterior wall of the third ventricle. Despite being histologically
low-grade, chordoid gliomas are often associated with poor outcome, as their stereotypic
location in the third ventricle makes resection challenging and efficacious adjuvant therapies
have not been developed. Here we performed genomic profiling on 13 chordoid gliomas and
identified a recurrent D463H missense mutation in PRKCA in all tumors, which localizes in the
kinase domain of the encoded protein kinase C alpha (PKCα). Expression of mutant PRKCA in
immortalized human astrocytes led to increased phospho-ERK and anchorage-independent
growth that could be blocked by MEK inhibition. These studies define PRKCA as a recurrently
mutated oncogene in human cancer and identify a potential therapeutic vulnerability in this
uncommon brain tumor.
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Chordoid glioma of the third ventricle is characterized by itsstereotypic location in the anterior third ventricle and itschordoid cellular architecture composed of glial fibrillary
acidic protein (GFAP)-positive tumor cells embedded within a
myxoid matrix, often accompanied by a dense lymphoplasma-
cytic inflammatory infiltrate1–3. Due to their intraventricular
location, they often obstruct flow of cerebrospinal fluid, leading to
symptoms associated with obstructive hydrocephalus, such as
intracranial hypertension, headache, nausea, vomiting, ataxia, and
cognitive changes. Despite being histologically low-grade (classi-
fied as grade II in the 2016 WHO Classification of Tumors of the
Central Nervous System) and well circumscribed without sub-
stantial invasion of surrounding brain tissue, chordoid gliomas
are associated with substantial morbidity and mortality. Their
proximity and adherence to critical regional structures makes
them difficult to safely resect. While gross total resection remains
a goal and can be curative, it can result in hypothalamic dys-
function or peri-operative complications including death4, 5.
Subtotal resection is often accompanied by tumor recurrence.
Optimal adjuvant therapy for subtotally resected or recurrent
tumors has not been established.
Chordoid gliomas were recently demonstrated to share
expression of the homeobox transcription factor TTF-1 (also
known as NKX2.1) with the organum vasculosum of the lamina
terminalis, suggesting a cellular origin of this neoplasm from
these specialized ependymal cells located along the anterior wall
of the third ventricle6. However, the molecular alterations that
drive these tumors are unknown7. Here we report genomic
analysis on a cohort of chordoid gliomas that was performed with
the goal of identifying new diagnostic and prognostic biomarkers,
as well as potential targets for molecularly tailored therapy for
these rare brain tumors.
Results
Chordoid glioma patient cohort. To investigate the molecular
pathogenesis of this rare brain tumor entity, we assembled a
cohort of archival tissue specimens from 13 patients diagnosed
with chordoid glioma of the third ventricle at medical centers
around the world. Clinical features of these 13 patients are listed
in Supplementary Table 1. The 6 male and 7 female patients
ranged in age at time of biopsy or resection from 34–67 years
(median 48 years). All tumors were located in the anterior third
ventricle and ranged in size from 2 to 6 cm. Representative
imaging features are shown in Fig. 1a and Supplementary Fig-
ure 1. Pathologic review confirmed the diagnosis of chordoid
glioma for each case. Representative histologic and immunohis-
tochemical features are shown in Fig. 1b and Supplementary
Figures 2 and 3. Patient outcomes ranged from early post-
operative death from surgical complications to mortality from
tumor recurrence within one year following subtotal resection to
long term recurrence-free survival.
PRKCA D463H mutation defines chordoid glioma. We per-
formed targeted next-generation sequencing as previously
described on genomic DNA isolated from the 13 tumors, as well
as matched normal tissue when available (two cases)8. In each
tumor, a G>C transversion mutation in the PRKCA gene was
identified causing a c.1387G>C, p.D463H substitution (reference
transcript NM_002737; Supplementary Table 2). This missense
mutation was verified to be somatic in both tumors with matched
normal tissue available for sequencing (CG-UCSF-1 and CG-
UCLA-1; Supplementary Figure 4). The mutant allele frequency
for this PRKCA D463H variant ranged from 12 to 42% in the 13
tumors, consistent with a somatic heterozygous mutation in all
cases. The cases with the highest PRKCA mutant allele
frequencies had genomic DNA that was isolated from areas his-
tologically visualized to contain a high tumor cell content. The
cases with lower PRKCA mutant allele frequencies had genomic
DNA that was isolated from areas that were visualized to contain
a more abundant lymphoplasmacytic inflammatory cell infiltrate.
The PRKCA locus is located at chromosome 17q24.2. No chro-
mosomal gains, losses, or copy-neutral loss of heterozygosity
involving this chromosomal locus were identified in any of the
tumors (Supplementary Figure 5, Supplementary Table 3).
Therefore, these data suggest that this PRKCA D463H mutation is
likely to be a clonal alteration in chordoid gliomas (i.e., present in
all tumor cells), indicating that it is probably an early or initiating
event in tumorigenesis.
Besides PRKCA mutation, no somatic nonsynonymous muta-
tions, amplifications, deletions, or rearrangements were identified
in any of the other 478 genes sequenced in the 13 chordoid
gliomas (Supplementary Data 1). Ten of the tumors demon-
strated a balanced diploid genome, while the remaining three
tumors contained isolated whole chromosome or arm-level gains
and losses, without focal regions of amplification or deletion
(Supplementary Figure 5, Supplementary Table 3). Specifically,
there were no alterations identified involving NF2 or RELA,
indicating that chordoid gliomas are genetically distinct from
most spinal and supratentorial ependymomas9. Additionally,
there were no alterations identified involving IDH1, IDH2, TP53,
ATRX, TERT, CIC, FUBP1, and NOTCH1, indicating that
chordoid gliomas are genetically distinct from the vast majority
of diffuse lower-grade gliomas in adults10. Also, there were no
alterations identified involving TSC1 or TSC2, indicating that
chordoid gliomas are genetically distinct from subependymal
giant cell astrocytomas11, another subtype of intraventricular
glioma that may show morphologic overlap with chordoid glioma
of the third ventricle (Supplementary Figure 2e).
PRKCA encodes protein kinase C alpha (PKCα), a cytoplasmic
serine/threonine kinase whose activity is modulated through
calcium and diacylglycerol binding domains (Fig. 1c). Only 95
tumors with confirmed somatic nonsynonymous mutations of
PRKCA are present amongst the 30,367 tumors with available
sequencing data for PRKCA in the version 81 release of the
Catalogue of Somatic Mutations in Cancer (COSMIC) database
(Supplementary Data 2). The mutations in these 95 tumors are
scattered throughout the gene without clustering in the kinase or
other functional domain, and none are affecting codon D463 as
seen in chordoid gliomas (Supplementary Figure 6). These 95
tumors are predominantly from cancer types with conspicuously
high somatic mutational burden such as melanoma and
microsatellite unstable gastrointestinal carcinoma, suggesting that
a majority of these PRKCA variants in tumors other than
chordoid gliomas are likely to be passenger or bystander
mutations.
Structural modeling of mutant PKCα. Amino acid D463 within
the kinase domain of PKCα functions as the proton acceptor
during the ATP hydrolysis reaction and is highly conserved from
yeast to humans (Fig. 1d). Structural modeling of PKCα illustrates
that substitution of aspartate with histidine at this codon
(D463H) results in a roughly isosteric side chain that contains a
proton acceptor in approximately the same location of one of the
oxygens in aspartate, if the imidazole ring is not doubly proto-
nated (Fig. 1e and Supplementary Figure 7). However, the proton
affinities of aspartate and histidine are markedly different (pKa of
approximately 4.0 and 6.5, respectively), and the histidine side
chain is commonly, but not always, doubly protonated at phy-
siological pH. This substitution is therefore likely to alter the
activity of the kinase function by perturbing the ATP hydrolysis
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reaction. Prior in vitro biochemical analysis of PKCα has shown
that synthetic isoforms harboring alanine or asparagine sub-
stitution at codon 463 (D463A or D463N) are kinase dead and
lack the ability to phosphorylate a peptide substrate relative to the
wildtype protein12. However, the functional consequence of the
aspartate to histidine substitution at this codon found in chordoid
gliomas (D463H) has not been evaluated to date, and we are
unaware of any other protein kinases or pseudo-kinases with
histidine at this position in the enzymatic pocket.
PRCKA D463H is an oncogenic mutation that drives ancho-
rage independent growth. To determine the functional effects of
this PRKCA mutation during tumorigenesis, we generated a
lentiviral expression vector for the human PRKCA cDNA. We
then used site-directed mutagenesis to introduce the D463H
mutation observed in chordoid gliomas, and additionally gener-
ated a separate expression vector harboring a D463A mutation.
As the amino acid side chain of alanine cannot function as a
proton acceptor, we hypothesized that this PRKCA D463A con-
struct may function as a kinase-dead mutant. Immortalized
human astrocytes were transduced with lentivirus and then
grown in soft agar to assay anchorage-independent growth, a
classic measure of cellular transformation13. Expression of wild-
type PRKCA led to only a small number of colonies, whereas
D463H mutant PRKCA yielded numerous colonies, indicating a
potent oncogenic effect of this mutation (Fig. 2a). No colonies
were observed in immortalized human astrocytes after infection
with empty vector or D463A mutant PRKCA. Lentiviral expres-
sion of D463H mutant PRKCA was also sufficient to drive
anchorage-independent growth of NIH-3T3 cells (Supplementary
Figure 8). These results indicate that D463H is an oncogenic,
gain-of-function mutation.
PRKCA D463H mutation induces activation of the MAP
kinase signaling pathway. To study the mechanisms by which
PRKCA D463H mutation drives tumorigenesis of chordoid glio-
mas, we transiently overexpressed wildtype and mutant PRKCA
in 293 T cells and immortalized human astrocytes. Reverse
transcription-PCR analysis after ectopic expression confirmed
expression of wild-type and mutant PRKCA transcripts (Sup-
plementary Figure 9). No differences in phosphorylated ERK
were observed in either cell type during in vitro growth in media
supplemented with 10% fetal bovine serum (Fig. 2b). In addition,
no increase in phosphorylated MARCKS, a known substrate of
PKCα kinase activity, was observed (Fig. 2b). However, when
stably transduced immortalized human astrocytes were serum
starved for 24 h, a significant increase in phospho-ERK was
observed for the D463H mutant relative to the wildtype and
D463A mutant isoforms (Fig. 2c). This was accompanied by a less
robust increase in phospho-Akt after serum starvation (Fig. 2c),
presumably related to the increased proliferative signaling
through the MAP kinase pathway. As opposed to the over-
expression of PKCα seen after transient transfection (Fig. 2b), a
significant increase in PKCα levels was not observed after stable
lentiviral transduction in immortalized human astrocytes
(Fig. 2c), possibly due to only low levels of overexpression or
auto-regulatory feedback mechanisms controlling the expression
of PKCα.
Next we performed immunohistochemistry for phospho-ERK
on the cohort of chordoid gliomas with PRKCA D463H mutation.
In each of the six chordoid gliomas that were assessed by
immunohistochemistry, robust staining for phospho-ERK was
observed, which was specific to the tumor cells and not present in
non-neoplastic endothelial cells and admixed inflammatory cells
(Fig. 3). The high level of phospho-ERK expression in chordoid
gliomas was equivalent to that seen in other glioma types
harboring known genetic alterations within the MAP kinase
signaling pathway, including pleomorphic xanthoastrocytoma
with BRAF V600E mutation and pilocytic astrocytoma with
KIAA1549-BRAF gene fusion (Fig. 3). Minimal phospho-ERK
staining was observed in sections of normal brain as well as other
glioma types harboring genetic alterations not associated with
MAP kinase pathway activation (Fig. 3), including clear cell
ependymoma with RELA gene fusion, which activates the nuclear
factor-kappa B signaling pathway. Thus, PRKCA D463H muta-
tion is likely to drive chordoid glioma, at least in part, by
activation of the MAP kinase signaling pathway, although this
may be a downstream consequence rather than direct phosphor-
ylation by mutant PKCα.
MEK inhibition blocks the oncogenic effects of mutant
PRCKA. We next tested the hypothesis that MEK inhibition
might be an effective therapy for chordoid glioma of the third
ventricle. Immortalized human astrocytes transduced with
D463H mutant PRKCA alongside a series of malignant glioma
cell lines harboring wildtype PRKCA alleles were grown in soft
agar containing either DMSO vehicle or 5 μM trametinib, a small
molecule inhibitor of MEK that is FDA-approved for the treat-
ment of melanoma. Trametinib effectively blocked the colony
formation of immortalized human astrocytes expressing D463H
mutant PRKCA, while causing only a mild reduction in colony
formation for the malignant glioma cell lines with wild-type
PRKCA alleles (Fig. 4).
Discussion
Together, these results identify PRKCA as a novel, recurrently
mutated oncogene in human cancer. PRKCA D463H mutation
appears to define chordoid glioma of the third ventricle and
genetically distinguishes it from all other brain tumor types that
have been studied to date. Thus, evaluation for this mutation may
help to distinguish chordoid glioma from other tumor entities
during pathologic assessment of suprasellar and intraventricular
neoplasms that are difficult to classify based on histologic features
alone.
The protein kinase C (PKC) family has been intensely inves-
tigated in the context of cancer ever since the discovery that it is a
receptor for phorbol esters, the potent tumor promoting com-
pounds derived from the seed oil of the Croton tiglium plant14.
Fig. 1 Chordoid glioma of the third ventricle is defined by PRKCA D463H mutation that localizes in the active site of the kinase domain in the encoded
protein kinase C alpha (PKCα). a T1-weighted post-contrast magnetic resonance image of a chordoid glioma. b Hematoxylin and eosin stained section of a
chordoid glioma. Scale bar, 40 μm. c Diagram of human PKCα with the location of the D463H mutation identified in each of the 13 chordoid gliomas shown.
d Amino acid sequence for PKCα in the region of D463 (highlighted in yellow) demonstrating a high degree of conservation from Homo sapiens to C.
elegans. e Structural model of the active site of the kinase domain for PKCα showing how the side chain of amino acid Asp463 sits within the ATP binding
pocket, where it functions as a proton acceptor during the ATP hydrolysis reaction. Substitution of Asp with His at this codon (D463H) is structurally
predicted to result in a side chain with a proton acceptor at nearly the same location, which may potentially alter kinase function through steric differences
or ability of the side chains to be protonated or deprotonated based on differential proton affinities
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This led to the hypothesis that the PKC genes are proto-
oncogenes whose activation by phorbol esters, endogenous
ligands, or genetic alteration promotes tumorigenesis. However,
recurrent somatic mutations in the genes encoding the various
PKC isoforms have not been found in any of the common human
cancer types studied to date. Only a small number of tumors with
confirmed somatic nonsynonymous mutations of PRKCA are
present amongst the greater than 30,000 tumors with available
sequencing data for PRKCA in the version 81 release of the
COSMIC database. These PRKCA variants are scattered
throughout the gene without clustering in the kinase or other
functional domain and are predominantly from cancer types with
conspicuously high somatic mutational burden such as melanoma
and microsatellite unstable gastrointestinal carcinoma (Supple-
mentary Figure 6), suggesting that a majority of these PRKCA
variants in tumors other than chordoid gliomas are likely to be
passenger or bystander mutations. Our study is the first to
demonstrate frequent somatic mutations in a PKC gene in a
human cancer subtype.
The PRKCA mutations in chordoid gliomas are all hetero-
zygous missense mutations that cluster at a single mutational
hotspot within the active site of the kinase domain in the encoded
PKCα protein. This genetic pattern of heterozygous missense
mutations that cluster at a mutational hotspot within a critical
functional domain is strongly suggestive that these are oncogenic,
gain-of-function mutations, as opposed to inactivating, loss-of-
function events that are typically truncating mutations scattered
throughout a gene and accompanied by loss of heterozygosity.
Thus, the genetic evidence indicates that PRKCA is likely to
function as an oncogene, rather than a tumor suppressor gene, in
chordoid gliomas. Additionally, our functional data show that
this D463H mutation is an oncogenic mutation sufficient to drive
anchorage independent growth in immortalized human astro-
cytes and NIH-3T3 cells. This is in contrast to the wildtype and
kinase-dead D463A mutant isoforms that did not promote
anchorage independent growth. Together, we believe this com-
bination of genetic and functional data prove that the D463H
variant is an oncogenic, gain-of-function mutation in PRKCA
that drives chordoid gliomas.
While the precise mechanism by which this PRKCA mutation
drives gliomagenesis remains to be elucidated, it does result in
increased MAP kinase pathway activation that may render
chordoid gliomas sensitive to MEK inhibitors. Overexpression of
the D463H mutant isoform was not found to increase phos-
phorylation of MARCKS, one of the known kinase substrates of
PKCα. We thus speculate that the PRKCA D463H mutation does
a
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Fig. 2 Mutant PRKCA induces ERK phosphorylation and is sufficient to drive anchorage-independent growth of immortalized human astrocytes. a Colony
formation in soft agar of immortalized human astrocytes after infection with lentivirus expressing empty vector, wildtype PRKCA, D463H tumor mutant
PRKCA, or D463A non-tumor mutant PRKCA. Images of representative wells (left) and quantitation of colony number per well (right) are shown. Error bars
represent standard deviation from the mean of six replicates derived from two independent experiments performed in triplicate. b Western blots on total
cell lysate from 293 T cells growing in 10% fetal bovine serum after transient transfection with empty vector, PRKCA wild-type, or PRKCA D463H mutant. c
Western blots on immortalized human astrocytes after lentiviral transduction and then serum starvation for 24 h before collection of total cell lysate
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-02826-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:810 |DOI: 10.1038/s41467-018-02826-8 |www.nature.com/naturecommunications 5
H&E Phospho-ERK
Chordoid glioma
PRKCA D463H
Normal brain
Pleomorphic
xanthoastrocytoma
BRAF V600E
Clear cell
ependymoma
RELA fusion
Fig. 3 Chordoid gliomas demonstrate high levels of phospho-ERK, equivalent to levels seen in other glioma types harboring oncogenic alleles of Ras-Raf-
MAP kinase pathway components. Shown are representative images of hematoxylin and eosin (H&E) staining and phospho-ERK immunohistochemistry on
a chordoid glioma with PRKCA D463H mutation (CG-UVA-1), normal brain, pleomorphic xanthoastrocytoma with BRAF V600E mutation, and clear cell
ependymoma with C11orf95-RELA gene fusion. Scale bar, 40 μm
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not function to simply increase the kinase activity of PKCα for its
canonical substrates, but rather causes a novel gain of function.
Possibilities for this neomorphic function that we speculate
include changing the specificity of the kinase activity for new
phosphorylation substrates, altering the pH at which the kinase
domain is active, or abolishing the kinase activity entirely but
promoting tumorigenesis through substrate trapping, acting as a
protein scaffold, or other novel kinase-independent mechanism.
Additional studies are ongoing in our laboratory to assess the
cellular mechanisms by which this mutation fuels tumorigenesis.
In summary, we have elucidated the genetic basis of chordoid
glioma of the third ventricle, provided mechanistic insight into
how this novel genetic alteration causes this tumor, and identified
a potential new therapeutic strategy based on the presence of this
defining genetic mutation.
Methods
Study population and tumor specimens. This study was approved by the
Committee on Human Research of the University of California, San Francisco,
with a waiver of patient consent. Thirteen chordoid gliomas were retrieved from
the pathology archives of our respective institutions, spanning years 2001 to 2015.
All tumor specimens had been fixed in 10% neutral buffered formalin and
embedded in paraffin. Clinical information regarding patient outcomes was
obtained from the electronic medical records of our respective institutions.
Pathologic re-review of all tumor samples was performed to confirm the diagnosis
by two expert neuropathologists (AP and DAS).
Immunohistochemistry. Immunohistochemistry was performed on whole for-
malin-fixed, paraffin-embedded tissue sections using the following antibodies:
GFAP (Dako, cat# Z0334, polyclonal, 1:3000 dilution), TTF-1 (Dako, cat# IS056,
clone 8G7G3/1, 1:500 dilution), and phospho-p44/42 ERK Thr202/Tyr204 (Cell
Signaling, cat #4370, clone D13.14.4E, 1:10,000 dilution). All immunostaining was
performed in a Leica Bond-Max automated stainer. Following antigen retrieval,
primary antibody was applied for 15 min followed by Bond-Max polymer for 15
min. Diaminobenzidine was used as the chromogen, followed by hematoxylin
counterstain.
Targeted next-generation DNA sequencing and mutational analysis. Genomic
DNA was extracted from formalin-fixed, paraffin-embedded blocks of tumor tissue
from 13 patients with chordoid glioma of the third ventricle using the QIAamp
DNA FFPE Tissue Kit (Qiagen). Genomic DNA was also extracted from leukocytes
in a peripheral blood sample from one of the patients (CG-UCSF-1) and a non-
neoplastic gastric biopsy specimen from one of the patients (CG-UCLA-1).
Capture-based next-generation DNA sequencing was performed at the University
of California, San Francisco Clinical Cancer Genomics Laboratory, using an assay
that targets all coding exons of 479 cancer-related genes, select introns of 47 genes,
and TERT promoter with a total sequencing footprint of 2.8 Mb (UCSF500 Cancer
Panel; Supplementary Data 1)8. Sequencing libraries were prepared from genomic
DNA, and target enrichment was performed by hybrid capture using a custom
oligonucleotide library (Nimblegen SeqCap EZ Choice). Captured libraries were
sequenced as paired-end 100 bp reads on an Illumina HiSeq 2500 instrument.
Duplicate sequencing reads were removed computationally to allow for accurate
allele frequency determination and copy number calling. The analysis was based on
the human reference sequence (NCBI build 37) using the following software
packages: BWA: 0.7.13, Samtools: 1.1 (using htslib 1.1), Picard tools: 1.97 (1504),
GATK: Appistry v2015.1.1–3.4.46–0-ga8e1d99, CNVkit: 0.7.2, Pindel: 0.2.5b8,
SATK: Appistry v2015.1.1–1-gea45d62, Annovar: v2016Feb01, Freebayes: 0.9.20,
and Delly: 0.7.215–22. Single nucleotide variants and insertions/deletions were
visualized and verified using Integrated Genome Viewer. Genome-wide copy
number analysis based on on-target and off-target reads was performed by CNVkit
and Nexus Copy Number (Biodiscovery)18.
PKCα structural modeling. The crystal structure of the kinase domain for human
PKCα has been previously resolved (pdb: 4RA4)23, except for a loop corresponding
to amino acids 617–633. A structural model incorporating this missing loop was
built using Protein Local Optimization Program (PLOP)24 and homology with the
human protein kinase A (PKA) crystal structure bound to a non-hydrolysable ATP
analog (pdb: 3O7L)25, which was subjected to a short minimization (steepest
descent). A model ATP was then built into the minimized PKCα by modifying the
AMP-PNP molecule. D463 from the resulting model was mutated in the pdb file to
D463H protonated at the epsilon position. Figures were produced using UCSF
Chimera, developed by the Resource for Biocomputing, Visualization, and Infor-
matics at the University of California, San Francisco (supported by NIGMS P41-
GM103311)26.
PRKCA cDNA expression vector construction and site-directed mutagenesis.
The pcDNA3-PRKCA wildtype expression vector was obtained from Addgene
(plasmid #21232). A human wildtype PRKCA cDNA (CCDS11664) with flanking
5′ BglII and 3′ NotI restriction sites was synthesized by GenScript and cloned into
the pCDF1-MCS2-EF1-Puro lentiviral expression vector (System Biosciences).
D463H and D463A mutations were engineered into the pCDNA3-PRKCA and
pCDF1-PRKCA constructs by site-directed mutagenesis using the QuikChange II
XL kit (Stratagene) as directed by the manufacturer. The entire coding sequence of
all expression vectors was verified by Sanger sequencing. Primer sequences used for
the mutagenesis reactions were as follows:
PRKCA D463H Fwd: 5′-GGAATCATTTATAGGCATCTGAAGTTAGATAAC−3′
PRKCA D463H Rev: 5′-GTTATCTAACTTCAGATGCCTATAAATGATTCC-3′
PRKCA D463A Fwd: 5′-GGAATCATTTATAGGGCTCTGAAGTTAGA
TAAC-3′
PRKCA D463A Rev: 5′-GTTATCTAACTTCAGAGCCCTATAAATGATTCC-3′.
Immortalized human astrocytes and cell culture. Human astrocytes immorta-
lized by retroviral transduction of hTERT, E6, and E7 proteins were generously
provided by Dr. Russ Pieper (University of California, San Francisco)13. 293 T and
NIH-3T3 cells were obtained directly from ATCC and were maintained in Dul-
becco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum at 37 °C in 5% CO2. Glioblastoma and other malignant glioma cell lines
harboring wildtype PRKCA alleles were obtained directly from ATCC (U87MG,
T98G, M059J), DSMZ (42MGBA), and Japan Health Sciences Foundation Health
Science Research Resources Bank (KNS-42, AM-38) and maintained in DMEM
supplemented with 10% fetal bovine serum at 37 °C in 5% CO2.
Lentiviral production and infection. Empty pCDF1 vector or pCDF1-PRKCA
wildtype and mutant expression vectors were co-transfected into 293 T cells with
pVSV-G and pFIV-34N helper plasmids (System Biosciences) using Fugene 6
(Roche) as described by the manufacturer. Virus-containing conditioned medium
was harvested 48 h after transfection, filtered, and used to infect recipient cells in
the presence of 10 μg/mL polybrene.
Western blot. Primary antibodies used were PKCα (Santa Cruz Biotechnology,
cat# sc-8393, clone H-7, 1:200 dilution), phospho-p44/42 ERK Thr202/Tyr204
(Cell Signaling, cat #4370, clone D13.14.4E, 1:200 dilution), phospho-MARKCS
Ser167/170 (Cell Signaling, cat #8722, clone D13E4, 1:100 dilution), phospho-Akt
Ser473 (Cell Signaling, cat #4060, clone D9E, 1:100 dilution), and α-tubulin
(Thermo Scientific, cat# 62204, clone DM1A, 1:1000 dilution). Protein was
extracted from 293 T cells or immortalized human astrocytes in RIPA buffer,
resolved by SDS–PAGE, and immunoblotted following standard biochemical
techniques. Complete uncropped blots are shown in Supplementary Figure 10.
Soft agar colony forming assay. PRKCA wildtype and mutant expressing lenti-
virus was added to exponentially growing NIH-3T3 cells or immortalized human
astrocytes in the presence of 10 μg/mL polybrene. At 24 h following infection,
20,000 cells were suspended in 0.3% agar in DMEM + 10% fetal bovine serum and
cast onto a bottom layer of 0.6% agar in DMEM+10% fetal bovine serum in six-
well tissue culture plates. For a subset of the experiments, DMSO vehicle or tra-
metinib (Selleck Chemicals) was added to the top agar layer to a final concentration
of 5 μM during casting. Soft agar plates were incubated in a humidified chamber at
37 °C containing 5% CO2 for 14 days. Colonies were imaged and counted on a
GelCount Colony Counter (Oxford Optronix).
Reverse transcription–PCR analysis of PRKCA expression. Total RNA was
isolated from 293 T cells at 48 h after transfection with wildtype or D463H mutant
PRCKA cDNA constructs using TRIzol (Life Technologies) according to the
manufacturer’s instructions. Reverse transcription–PCR (RT–PCR) was performed
on the total RNA using SuperScript III One-Step RT–PCR System (Life Tech-
nologies) to amplify PRKCA mRNA transcripts. RRT–PCR products were
sequenced using BigDye terminator chemistry (Applied Biosystems) following
standard techniques. Primer sequences used for RT–PCR amplification and
sequencing of PRKCA mRNA transcripts were as follows:
PRKCA RT–PCR Fwd: 5′-CCTCATGTACCACATTCAGCA-3′
PRKCA RT–PCR Rev: 5′-TCTGGGGCGATATAATCTGG-3′.
Data availability. Sequence data from the 13 chordoid gliomas have been
deposited at the European Genome-Phenome Archive (EGA) under accession
number EGAS00001002733. All PRKCA expression constructs used in this study
have been deposited with Addgene for public distribution. All other remaining data
are available within the Article and Supplementary Files, or available from the
authors upon request.
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